Polar Asset Management Partners Inc. lessened its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 159,710 shares of the medical instruments supplier's stock after selling 58,190 shares during the period. Polar Asset Management Partners Inc. owned about 0.29% of Glaukos worth $23,947,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. ProShare Advisors LLC grew its stake in shares of Glaukos by 44.0% in the 4th quarter. ProShare Advisors LLC now owns 14,869 shares of the medical instruments supplier's stock valued at $2,229,000 after buying an additional 4,542 shares in the last quarter. Nicholas Investment Partners LP increased its position in shares of Glaukos by 54.2% during the fourth quarter. Nicholas Investment Partners LP now owns 31,961 shares of the medical instruments supplier's stock valued at $4,792,000 after purchasing an additional 11,237 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of Glaukos by 0.9% during the 4th quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after acquiring an additional 2,665 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Glaukos by 3.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,349 shares of the medical instruments supplier's stock worth $4,551,000 after buying an additional 984 shares during the period. Finally, Lazard Asset Management LLC raised its stake in shares of Glaukos by 228.2% in the fourth quarter. Lazard Asset Management LLC now owns 13,911 shares of the medical instruments supplier's stock valued at $2,085,000 after acquiring an additional 9,673 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.
Glaukos Stock Down 1.0%
Shares of NYSE:GKOS opened at $91.45 on Thursday. The company has a 50 day moving average price of $94.05 and a two-hundred day moving average price of $126.57. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $5.23 billion, a PE ratio of -31.86 and a beta of 0.83. Glaukos Co. has a 52 week low of $77.10 and a 52 week high of $163.71.
Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same period in the previous year, the firm earned ($0.70) earnings per share. The company's revenue was up 24.6% on a year-over-year basis. Analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.
Insider Activity
In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on GKOS. Needham & Company LLC dropped their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Mizuho reduced their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Morgan Stanley dropped their price objective on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Truist Financial reissued a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Finally, Stifel Nicolaus cut their price target on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $134.67.
View Our Latest Analysis on Glaukos
About Glaukos
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
